In Vitro Fertilization Ivf MarketSize, Share & Industry Analysis, 2026-2034By TypeBy DevicesBy ReagentsBy End-userBy Age Group

In vitro fertilization is an assisted reproductive procedure in which eggs are retrieved from the ovaries and fertilized with sperm outside the body, with the resulting embryo transferred to the uterus; the category covers the instruments, culture media and cryopreservation systems used at each stage of the procedure alongside intrauterine insemination and donor-egg variants performed under the same clinical protocol. Buyers are fertility clinics, hospital reproductive medicine units and clinical research centers that purchase imaging, aspiration, micromanipulation and cryostorage equipment together with the consumable media each cycle requires.

The global in vitro fertilization ivf market stood at USD 30 billion in 2025. A forecast-period rate of 6.99% takes it to USD 55.14 billion by 2034, and the study reports every year in between, passing USD 20.91 billion in 2020, USD 27.92 billion in 2024, USD 32.1 billion in 2026 and USD 42.07 billion in 2030.

The type mix shifts over the period. Intracytoplasmic Sperm Injection is the largest line in 2025 at USD 16.5 billion, a 55% share, moving to USD 28.67 billion and 52% by 2034. IVF Using Donor Eggs grows fastest at 10.99%, taking its share from 15% to 21%, while Intrauterine Insemination grows slowest at 5.75%. The lines gaining share are IVF Using Donor Eggs. Intrauterine Insemination and Intracytoplasmic Sperm Injection lose share without losing revenue.

The devices split puts Imaging Systems first, at USD 9 billion and 30% of revenue in 2025, rising to USD 14.89 billion and 27% in 2034. Cryosystem grows faster at 11.64% against 5.76%, moving from 15% of revenue to 21.98% by 2034. It cuts the same total as the type axis from a different commercial angle, so revenue does not add across the two.

North America is the largest region at 32% of 2025 revenue, worth USD 9.6 billion and reaching USD 15.99 billion by 2034. Asia Pacific follows at 30%, moving from USD 9 billion to USD 18.75 billion, and Middle East and Africa is the smallest at 6%. Share shifts toward Asia Pacific and Latin America over the forecast period, so the regional split repays a close reading.

Behind these figures sit five regions, three type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is triangulated from published sources and category proxies, with no independently sourced count behind it, and the same applies to the segment, regional and country breakdowns drawn from it.

• Revenue grows from USD 30 billion in 2025 to USD 55.14 billion in 2034, a compound annual rate of 6.99%, having reached USD 27.92 billion in 2024 from USD 20.91 billion in 2020.
• The largest line by type is Intracytoplasmic Sperm Injection, worth USD 16.5 billion and 55% of revenue in 2025, rising to USD 28.67 billion and 52% by 2034.
• Fastest growth on the type axis belongs to IVF Using Donor Eggs: 10.99% a year, USD 4.5 billion to USD 11.58 billion, and a share moving from 15% to 21%.
• Against a base case of USD 55.14 billion in 2034, the study also reports a bear case at USD 44.58 billion and a bull case at USD 66.78 billion, with the assumptions behind each set out separately.
• 32% of 2025 revenue is generated in North America, worth USD 9.6 billion and rising to USD 15.99 billion by 2034; Middle East and Africa is smallest at 6%.
• 81.98% of North America's base-year revenue comes from the United States alone: USD 7.87 billion in 2025, rising to USD 12.79 billion by 2034, which is why it is that region's worked example.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

Three things move over 2026-2034, and they are worth separating: the type mix, the regional balance, and the 6.99% compounding underneath both.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

IVF Using Donor Eggs outpaces Intrauterine Insemination. IVF Using Donor Eggs grows at 10.99% across 2026-2034 against 5.75% for Intrauterine Insemination, the widest spread on the type axis. By 2034 the two sit at 21% and 27.01% of revenue, against 15% and 30% in 2025. Revenue rises on both sides; USD 4.5 billion to USD 11.58 billion and USD 9 billion to USD 14.89 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.

Asia Pacific and Latin America gain regional share. Asia Pacific moves from 30% of revenue in 2025 to 34.01% in 2034, worth USD 9 billion rising to USD 18.75 billion; Latin America moves from 6% of revenue in 2025 to 7% in 2034, worth USD 1.8 billion rising to USD 3.86 billion. Share moves off the others in turn: North America at 32% moving to 29%, Europe at 26% moving to 24%, Middle East and Africa at 6% moving to 6%, each still growing in revenue terms. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.

Growth compounds at 6.99% without a step change. Fifteen years of revenue run USD 20.91 billion in 2020, USD 27.92 billion in 2024, USD 30 billion in 2025, USD 32.1 billion in 2026, USD 42.07 billion in 2030 and USD 55.14 billion in 2034. Against 7.49% through the historical period, the 6.99% forecast rate is a continuation; no year in the series interrupts it. That moves the planning question away from timing a turn and onto the type and regional mixes, where the actual movement is.

The fastest line decides the blended rate

Separate the 6.99% into its parts and three show up: an already-large base compounding, the type mix moving toward its faster lines, and regional growth landing unevenly.

The bear case and what drives it

Upside case: USD 66.78 billion by 2034

One type line carries the market

In North America, 32% of global revenue puts 2025 at USD 9.6 billion on the way to USD 15.99 billion by 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share stands at 29%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Intracytoplasmic Sperm Injection leads here as it does globally, at 55% of 2025 revenue, and IVF Using Donor Eggs again grows fastest at 10.99%. Revenue for North America is broken out by every segmentation axis and by country in the full report.

81.98% of North America's base-year revenue comes from the United States; USD 7.87 billion, rising to USD 12.79 billion by 2034. 81.98% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Against regional totals of USD 9.6 billion in 2025 and USD 15.99 billion in 2034, it is the country the full report breaks out in detail.

Composition here matches the global split: the largest line is Intracytoplasmic Sperm Injection at 55% of 2025 revenue, easing to 52% by 2034, and the fastest is IVF Using Donor Eggs at 10.99%, from 15% to 21%. Its 81.98% weight in North America means those movements carry straight into the regional totals. Revenue by type for the United States is reported separately in the full report.

In the United States, IVF-related devices, culture media, and embryology instruments are regulated by the Food and Drug Administration under its medical device framework, with classification determining whether a supplier needs premarket notification or premarket approval before marketing a product. Manufacturers must also comply with the FDA's quality system regulation covering design controls, labelling, and traceability. Fertility clinics and embryology laboratories operate under the Clinical Laboratory Improvement Amendments, which set personnel, proficiency testing, and quality standards for the laboratory side of treatment. Success-rate reporting to the Centers for Disease Control adds a public accountability layer that sits alongside device approval, though it does not substitute for it.

The suppliers tracked in this study (Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher ScientificInc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Limited (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker CompanyInc. (US), Kitazato Corporation (Japan), Rocket Medical plc (UK), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), FERTIPRO NV(Belgium) and Gynotec B.V. (Netherlands)) compete in the United States across the type lines above. Two different problems sit on the same axis: holding Intracytoplasmic Sperm Injection at 55% of 2025 revenue, and taking IVF Using Donor Eggs while it grows at 10.99%. Per-company positioning and share at country level are in the full report only.

Canada is sized at USD 1.44 billion in 2025, rising to USD 2.4 billion by 2034; 4.8% of global revenue and 15% of North America. It is reported separately from the United States across every segmentation axis in the full report.

In Europe, 26% of global revenue puts 2025 at USD 7.8 billion rising to USD 13.23 billion in 2034. Among the five regions it ranks third by revenue in both years.

Share settles at 24% in 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

The type mix reported at global level applies here, with Intracytoplasmic Sperm Injection the largest line at 55% of 2025 revenue and IVF Using Donor Eggs the fastest-growing at 10.99%. The full report breaks Europe out along every axis and by country.

USD 3.12 billion of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 5.03 billion by 2034. 40% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 7.8 billion in 2025 and USD 13.23 billion in 2034, it is the country the full report breaks out in detail.

Germany buys along the same lines as the market globally; Intracytoplasmic Sperm Injection first at 55% of 2025 revenue and 52% in 2034, IVF Using Donor Eggs fastest at 10.99% on a share moving from 15% to 21%. Because the country carries 40% of Europe, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The full report reports Germany by type separately.

In Germany, medical devices used in IVF, including catheters, culture media, and cryopreservation equipment, fall under the EU Medical Device Regulation and require CE marking following a conformity assessment appropriate to their risk class. The national competent authority, BfArM, oversees market surveillance, while notified bodies certify higher-risk devices against harmonised standards covering quality management systems. Clinical practice itself is bounded by the Embryo Protection Act, a national law that restricts how embryos may be created, stored, and used, shaping what a supplier's product can be marketed to do inside a German laboratory. Labelling must reflect both the device's intended purpose and its conformity status.

The suppliers tracked in this study (Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher ScientificInc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Limited (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker CompanyInc. (US), Kitazato Corporation (Japan), Rocket Medical plc (UK), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), FERTIPRO NV(Belgium) and Gynotec B.V. (Netherlands)) compete in Germany across the type lines above. The commercially relevant division is 55% of 2025 revenue in Intracytoplasmic Sperm Injection, where the volume is, against 10.99% growth in IVF Using Donor Eggs, where share moves. That makes Europe a 26% share of 2025 global revenue, USD 7.8 billion rising to USD 13.23 billion, for any supplier deciding where to concentrate.

Within Europe, the United Kingdom accounts for 25% of regional revenue and 6.5% of the global total, worth USD 1.95 billion in 2025 and USD 3.18 billion by 2034.

30% of the global in vitro fertilization ivf market sits in Asia Pacific in 2025, worth USD 9 billion on the way to USD 18.75 billion by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

Share climbs to 34.01% by 2034, at a pace above the 6.99% global rate, so this region warrants separate treatment and should not be scaled off the total.

The type mix reported at global level applies here, with Intracytoplasmic Sperm Injection the largest line at 55% of 2025 revenue and IVF Using Donor Eggs the fastest-growing at 10.99%. Per-axis and per-country detail for Asia Pacific sits in the full report.

USD 3.6 billion of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 8.44 billion by 2034. 40% of the region in the base year makes it the largest market here without making it the region. Set against USD 9 billion and USD 18.75 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Demand in China follows the type mix reported at global level: Intracytoplasmic Sperm Injection is the largest line at 55% of 2025 revenue, moving to 52% by 2034, while IVF Using Donor Eggs grows fastest at 10.99% and takes its share from 15% to 21%. Since 40% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-type revenue for China appears on its own in the full report.

In China, medical devices, reagents, and culture media used in IVF are regulated by the National Medical Products Administration, which assigns products to a risk-based classification and requires registration before a supplier may sell into the market. Registration typically calls for clinical evaluation data, manufacturing quality certification, and Chinese-language labelling that matches the approved product description. Separately, the National Health Commission licenses assisted reproductive technology clinics and sets rules on how embryology laboratories must operate, so a device's registration status is only one part of what a supplier needs to bring a product into clinical use. Imported products face additional scrutiny of their manufacturing facilities before registration is granted.

Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher ScientificInc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Limited (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker CompanyInc. (US), Kitazato Corporation (Japan), Rocket Medical plc (UK), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), FERTIPRO NV(Belgium) and Gynotec B.V. (Netherlands) are the suppliers covered in China. Two different problems sit on the same axis: holding Intracytoplasmic Sperm Injection at 55% of 2025 revenue, and taking IVF Using Donor Eggs while it grows at 10.99%. Weighting toward Asia Pacific means competing for 30% of 2025 global revenue, a base of USD 9 billion moving to USD 18.75 billion across the forecast period.

Within Asia Pacific, Japan accounts for 35% of regional revenue and 10.5% of the global total, worth USD 3.15 billion in 2025 and USD 5.63 billion by 2034.

6% of the global in vitro fertilization ivf market sits in Latin America in 2025, worth USD 1.8 billion rising to USD 3.86 billion in 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

Share climbs to 7% by 2034, because it outgrows the market's 6.99%; the revenue added here is disproportionate to where the region started.

Within the region the type split tracks the global one; 55% of 2025 revenue in Intracytoplasmic Sperm Injection, fastest growth of 10.99% in IVF Using Donor Eggs. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.

Brazil is the largest market within Latin America, generating USD 0.9 billion in 2025 and projected to reach USD 1.93 billion by 2034. At 50% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. The region itself runs USD 1.8 billion to USD 3.86 billion over the same period, and this is the market carrying the country-level detail in the full report.

Brazil buys along the same lines as the market globally; Intracytoplasmic Sperm Injection first at 55% of 2025 revenue and 52% in 2034, IVF Using Donor Eggs fastest at 10.99% on a share moving from 15% to 21%. Because the country carries 50% of Latin America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The full report reports Brazil by type separately.

In Brazil, medical devices and reagents used in IVF procedures are regulated by ANVISA, the national health surveillance agency, which requires product registration based on risk classification along with evidence of conformity to applicable technical standards before a device can be marketed. Manufacturers must also demonstrate compliance with Good Manufacturing Practice requirements, verified through facility inspection for higher-risk categories. The Federal Council of Medicine issues separate resolutions governing how assisted reproduction is practised clinically, covering matters such as embryo handling and clinic accreditation, so a supplier's registration with ANVISA sits alongside professional rules that shape how its products are actually used in treatment.

Competition in Brazil runs between the suppliers this study tracks: Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher ScientificInc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Limited (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker CompanyInc. (US), Kitazato Corporation (Japan), Rocket Medical plc (UK), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), FERTIPRO NV(Belgium) and Gynotec B.V. (Netherlands). The commercially relevant division is 55% of 2025 revenue in Intracytoplasmic Sperm Injection, where the volume is, against 10.99% growth in IVF Using Donor Eggs, where share moves. Weighting toward Latin America means competing for 6% of 2025 global revenue, a base of USD 1.8 billion moving to USD 3.86 billion across the forecast period.

Mexico is sized at USD 0.54 billion in 2025, rising to USD 1.16 billion by 2034; 1.8% of global revenue and 30% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

6% of the global in vitro fertilization ivf market sits in Middle East and Africa in 2025, worth USD 1.8 billion with USD 3.31 billion projected for 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

6% of global revenue sits here in 2034, below the 2025 level, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Segment composition follows the global pattern: Intracytoplasmic Sperm Injection largest at 55% of 2025 revenue, IVF Using Donor Eggs fastest at 10.99%. Middle East and Africa is reported axis by axis and country by country in the full study.

35% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.63 billion, rising to USD 1.16 billion by 2034. At 35% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Set against USD 1.8 billion and USD 3.31 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Composition here matches the global split: the largest line is Intracytoplasmic Sperm Injection at 55% of 2025 revenue, easing to 52% by 2034, and the fastest is IVF Using Donor Eggs at 10.99%, from 15% to 21%. Its 35% weight in Middle East and Africa means those movements carry straight into the regional totals. Per-type revenue for Saudi Arabia appears on its own in the full report.

In Saudi Arabia, medical devices and reagents used in IVF are regulated by the Saudi Food and Drug Authority, which requires a marketing authorisation before a product may be sold, based on a risk classification broadly aligned with international frameworks. Suppliers must show conformity to recognised technical standards and maintain labelling that matches the authorised product file. The Ministry of Health separately licenses fertility clinics and sets clinical rules for assisted reproduction, reflecting the country's own ethical and religious guidance on embryo handling, so device authorisation and clinical practice are governed through two distinct but connected channels.

The suppliers tracked in this study (Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher ScientificInc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Limited (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker CompanyInc. (US), Kitazato Corporation (Japan), Rocket Medical plc (UK), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), FERTIPRO NV(Belgium) and Gynotec B.V. (Netherlands)) compete in Saudi Arabia across the type lines above. Intracytoplasmic Sperm Injection, at 55% of 2025 revenue, is where the volume sits, and IVF Using Donor Eggs, growing at 10.99%, is where position changes hands over the forecast period. That makes Middle East and Africa a 6% share of 2025 global revenue, USD 1.8 billion rising to USD 3.31 billion, for any supplier deciding where to concentrate.

The United Arab Emirates is sized at USD 0.45 billion in 2025, rising to USD 0.83 billion by 2034; 1.5% of global revenue and 25% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, Devices, Reagents, End-User, Age Group, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.